SCHEMBL4165161

SCHEMBL4165161

CN(O)C(=O)c1cc2c(NS(=O)(=O)c3ccccc3)cn(Cc3ccc(F)cc3)c2cn1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41
LIMK2 P53671 1/20 0.40
TP53 P04637 2/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
METAP2 P50579 1/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
SERPINE1 P05121 1/20 0.38
POLB P06746 1/20 0.38
ADAM17 P78536 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4175427 0.88 BRD4 (0.40) MEN1KMT2AMAPTSMN1; SMN2SERPINE1
SCHEMBL4161028 0.87 MEN1 (0.42) MEN1KMT2APIK3CAMTORMETAP2
SCHEMBL1684246 0.83 POLB (0.40) MEN1KMT2ATP53MAPTHTT
SCHEMBL1684266 0.79 SLC22A12 (0.40) PIK3CAMTORTP53SMN1; SMN2POLB
SCHEMBL1684265 0.79 RXFP1 (0.41) MEN1KMT2ATP53MAPTSMN1; SMN2
SCHEMBL4166420 0.79 LMNA (0.37) MEN1KMT2ATP53MAPTSMN1; SMN2
SCHEMBL4798568 0.76 THRB (0.39) MAPTSERPINE1POLB
SCHEMBL1684250 0.76 KMT2A (0.42) KMT2ATP53SERPINE1POLB
SCHEMBL4166990 0.75 HDAC1 (0.41) MEN1KMT2AMAPTSMN1; SMN2SERPINE1
SCHEMBL4809910 0.75 PPARD (0.38) TP53MAPTSERPINE1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC 2009-07-02 US claimed
EP-1943249-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME Pfizer Products Incorporated (US) 2008-07-16 EP claimed
WO-2007039802-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER PRODUCTS INC. (US) 2007-04-12 WO claimed
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC 2009-07-02 US disclosed
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC 2009-07-02 US disclosed
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC 2009-07-02 US disclosed
WO-2007039802-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER PRODUCTS INC. (US) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME IMPDH1, IMPA1, TYMP MEN1 4721/4885KMT2A 1368/4885PIK3CA 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.